These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 3900245

  • 1. In vivo responses to Mycobacterium leprae: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions.
    Longley J, Haregewoin A, Yemaneberhan T, Warndorff van Diepen T, Nsibami J, Knowles D, Smith KA, Godal T.
    Int J Lepr Other Mycobact Dis; 1985 Sep; 53(3):385-94. PubMed ID: 3900245
    [Abstract] [Full Text] [Related]

  • 2. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor.
    Modlin RL, Hofman FM, Horwitz DA, Husmann LA, Gillis S, Taylor CR, Rea TH.
    J Immunol; 1984 Jun; 132(6):3085-90. PubMed ID: 6327818
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients.
    Mutis T, Kraakman EM, Cornelisse YE, Haanen JB, Spits H, De Vries RR, Ottenhoff TH.
    J Immunol; 1993 May 15; 150(10):4641-51. PubMed ID: 8482851
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be overcome in vitro by stimulation with fractionated M. leprae components.
    Ottenhoff TH, Converse PJ, Gebre N, Wondimu A, Ehrenberg JP, Kiessling R.
    Eur J Immunol; 1989 Apr 15; 19(4):707-13. PubMed ID: 2659369
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery.
    Sridevi K, Khanna N, Chattree V, Pal PC, Haq W, Rao DN.
    Int Immunopharmacol; 2003 Nov 15; 3(12):1589-600. PubMed ID: 14555284
    [Abstract] [Full Text] [Related]

  • 9. Evidence for the presence of M. leprae reactive T lymphocytes in patients with lepromatous leprosy.
    Nath I, Sathish M, Jayaraman T, Bhutani LK, Sharma AK.
    Clin Exp Immunol; 1984 Dec 15; 58(3):522-30. PubMed ID: 6391762
    [Abstract] [Full Text] [Related]

  • 10. Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients.
    Shinde SR, Chiplunkar SV, Butlin R, Samson PD, Deo MG, Gangal SG.
    Int J Lepr Other Mycobact Dis; 1993 Mar 15; 61(1):51-8. PubMed ID: 8326181
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy.
    Sieling PA, Abrams JS, Yamamura M, Salgame P, Bloom BR, Rea TH, Modlin RL.
    J Immunol; 1993 Jun 15; 150(12):5501-10. PubMed ID: 8515073
    [Abstract] [Full Text] [Related]

  • 12. A follow up of T-cell subsets and of anti-M. leprae antibody titer as measured by the FLA-ABS test in Melanesian leprosy patients under polychemotherapy.
    Garraud O, Ribierre O, Bach MA.
    Int J Lepr Other Mycobact Dis; 1986 Mar 15; 54(1):38-45. PubMed ID: 2940306
    [Abstract] [Full Text] [Related]

  • 13. The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes.
    Van Voorhis WC, Kaplan G, Sarno EN, Horwitz MA, Steinman RM, Levis WR, Nogueira N, Hair LS, Gattass CR, Arrick BA, Cohn ZA.
    N Engl J Med; 1982 Dec 23; 307(26):1593-7. PubMed ID: 6216407
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The immunobiology of leprosy.
    Kaplan G, Cohn ZA.
    Int Rev Exp Pathol; 1986 Dec 23; 28():45-78. PubMed ID: 3516911
    [Abstract] [Full Text] [Related]

  • 16. In vitro lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. The effect of dapsone treatment on the response to Mycobacterium leprae antigens, tuberculin purified protein derivative and non-mycobacterial stimulants.
    Reitan LJ, Closs O, Belehu A.
    Int J Lepr Other Mycobact Dis; 1982 Dec 23; 50(4):455-67. PubMed ID: 6763003
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K, Neena K, Chitralekha KT, Arif AK, Tomar D, Rao DN.
    Int Immunopharmacol; 2004 Jan 23; 4(1):1-14. PubMed ID: 14975355
    [Abstract] [Full Text] [Related]

  • 19. Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions.
    Bjune G, Barnetson RS, Ridley DS, Kronvall G.
    Clin Exp Immunol; 1976 Jul 23; 25(1):85-94. PubMed ID: 791549
    [Abstract] [Full Text] [Related]

  • 20. In situ identification of activated Ta1+ T lymphocytes in human leprosy skin lesions.
    Shen JY, Hofman FM, Gunter JR, Modlin RL, Rea TH.
    Int J Lepr Other Mycobact Dis; 1987 Sep 23; 55(3):494-8. PubMed ID: 2443587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.